創薬流通市場「薬市楽座」
安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。
創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。
なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。
| 掲載日 | シーズ番号 | 作用機序 | 適応症 | 投与経路 | モダリティ | 開発ステージ | 備考 | |
|---|---|---|---|---|---|---|---|---|
| 19/11/15 | GEM129 | Immuno-modulator | Anogenital warts, Actinic keratosis, Basal cell carcinoma | Topical | Small molecule |
Phase 2 | · The first product on the market that combines the therapeutic benefits of a marketed immunomodulator with an innovative transparent bioadhesive film. · When applied to the lesion, generates a transparent bioadhesive film, which acts as a reservoir or matrix release and reduces the local reactions and increases the permanence of the product in the action site. · The results of non-clinical studies demonstrate that GEM129 has a better safety profile with an equivalent efficacy than its reference product. Clinical studies on-going. |
問合せ |
| 19/11/15 | GEM128 | Antibiotic | Primary and secondary skin infection - canine pyoderma | Topical | Small molecule |
Clinical for animal | · The first medicine on the market that combines the therapeutic benefits of a marketed antibiotic with an innovative film-forming, long-lasting delivery technology. · When applied to the lesion, generates a transparent film that acts as a bioadhesive sustained release matrix maintaining the optimum concentration of the antibiotic in the skin for a period of 6-8 hours. · The bioadhesive film generated reduces product removal from the area due to animal scratching, licking or friction with skin folds which contribute in improving the treatment efficacy. Also, reduces oral antibiotic overusing by improving topical treatment with this innovative technology. *Canine bacterial infections of the skin, including superficial pyoderma |
問合せ |
| 19/11/15 | GEM127 | Antibiotic | Refer to Note | Topical | Small molecule |
Launched | Indication: Primary and secondary skin infection - Impetigo, folliculitis, furunculosis (human use) Note: · The first product on the market that combines the therapeutic benefits of a marketed antibiotic with an innovative transparent film-forming and bioadhesive delivery technology. · When applied to the lesion, generates a film that acts as a bioadhesive sustained release matrix, maintaining the optimum concentration of antibiotic in the skin for a period of 6-8 hours. · The bioadhesive film generated prevents the removal of the antibiotic from the lesion and acts as a protective dressing that prevents infection spreading. |
問合せ |
| 19/11/05 | GEM126 | Selective estrogen receptor downregulator | ER+ advanced or metastatic breast cancer | Oral | Small molecule | Phase 1 | • Both antagonizes and degrades ER alpha in cells to achieve the goal of blocking the estrogen signaling pathway. • Favorable oral pharmacokinetics in healthy rats and dogs whereas fulvestrant has a low bioavailability and can only be intramuscularly administrated. • Favorable preclinical in vitro and vivo single agent efficacy in inhibiting ER+ breast cancer cell proliferation, in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer. • Highly selective, no effect on other kinases and receptors. • Can be licensed to global area with some limitation |
問合せ |
| 19/11/05 | GEM124 | Improves endothelial cell function and cellular fluidity. Antiatherosclerotic, antiinflammatory, anti-fibrotic, fat-targeting composition | 1) Atherosclerosis （#） 2) Treatment of NASH （Stage F2-F3） Fibrosis with no worsening of fibrosis | Oral | Small molecules | Preclinical | 1) Developed to target vulnerable, high risk plaques while also reducing LDL cholesterol, increasing HDL cholesterol and reducing Triglycerides. (#) Future indications: primary prevention of Heart Attack, Stroke and Death and Secondary Prevention of Myocardial Infarction in Europe. US Patent to treat Atheroslersis is valid until 2035. 2) Concurrently being developed to treat liver inflammation, fibrosis and fat accumulation while also reducing LDL cholestrol and Triglycerides. *May be used in combination with other drugs, such as Intercept's Ocaliva that increases Triglycerides or Gilead's NASH candidate that increses LDL cholesterol. |
問合せ |
| 19/10/29 | GEM123 | miRNA targeting cancer stem cells | colon cancer | i.v. | Nucleic acid |
Preclinical | GEM123 suppressed the stemness of cancer cells by inhibiting KLF5 expression, and provoked apoptosis and cycle arrest through the downregulation of TFDP1and MDM2 expressions. GEM123 also inhibited tumor growth with no apparent side effect in mouse model. |
問合せ |
| 19/10/29 | GEM122 | Natural Killer T (NKT) cell-mediated anti-tumor responses | Solid cancer | i.v. | Cell Therapy |
Phase 1 | GEM122 shows its anti-tumor activity by activating endogenous NKT cells. Activated NKT cells strongly enhance both innate and acquired immune systems, induce the long-term immune memory and promote accumulation of TILs (tumor infiltrating lymphocytes) in tumor sites. GEM122 consists of a novel NKT ligand and a novel APC. The novel NKT ligand shows much stronger NKT activity than the previous NKT ligand, α-Galactosylceramide and by using the novel APC, the cellular product can be manufactured efficiently as well. |
問合せ |
| 19/10/23 | GEM121 | Modified phytic acid (inositol hexaphosphate: IP6) | Cancer | Oral | Small molecule |
Preclinical | · Demonstrated selective anti-cancer effects including apoptosis and inhibition of Akt activation. · In vivo study using mice with adult T-cell leukemia showed reduction of the size of the cancer. |
問合せ |
| 19/10/23 | GEM120 | Inhibition of membrane binding of Pr55Gag | HIV | i.v. | Small molecule |
Preclinical | · Inhibited the membrane localization of Pr55Gag and stopped budding of HIV virus. · Captures HIV in immune cells and induces apoptosis of the HIV-infected immune cells. |
問合せ |
| 19/10/23 | GEM119 | Inactivation of end-product of lipid peroxidation | Cerebral Infarction | i.v. | Small molecule |
Preclinical | · Showed more potent 4-hydroxynonenal - quenching activity compared with carnosine or histidine hydrazide (HH) at 30min incubation. · GEM119 ( ip administration) rescued the hippocampal CA1 cell death of transient cerebral ischemia model of Mongolian gerbil whereas HH did not. |
問合せ |